Actively Recruiting
Microbiota Footprint and Frailty Phenotype in Virologically Suppressed People Living With HIV
Led by Hôpital Européen Marseille · Updated on 2025-09-25
132
Participants Needed
1
Research Sites
325 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Analysis of gut microbiota becomes more and more accessible in recent years. Experimental data in both animal and human studies have demonstrated that imbalance of the gut microbiota which is called symbiosis may participate in an accelerated procedure of ageing as well as the expression of frailty phenotype. People living with HIV (PLHIV) present markers of phenotypic frailty on average 10 years before uninfected people. In this population structural and functional modifications of GALT (Gut Associated Lymphoid Tissue) are observed early after HIV infection and persist despite virological suppression on ART (AntiRetroviral Treatment). These GALT modifications are associated with microbial translocation that is also correlated with immune activation and dysbiosis. The objective of study is to explore gut microbiota of PLWH over 5 years, as well as to study associations of its longitudinal evolution with frailty markers and burden of comorbidities.
CONDITIONS
Official Title
Microbiota Footprint and Frailty Phenotype in Virologically Suppressed People Living With HIV
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Individuals infected with HIV in the stable phase of their disease (no disease outbreak or treatment change within 3 months before inclusion)
- Receiving ongoing HIV outpatient follow-up at the participating center
- Virological suppression with HIV RNA below 50 copies/mL for at least 5 years (allowing blips under 200 copies/mL)
- Aged 55 years or older at study start
- CD4+ T cell nadir above 200 cells/mm3
- Provide free and informed written consent
- Affiliated with or benefiting from a social security scheme
You will not qualify if you...
- Use of antibiotics, probiotics, prebiotics, or other treatments affecting gut microbiota within 2 months before stool sampling
- Not regularly followed at the participating center
- Only hospitalized for full inpatient stay (not outpatient)
- In primary HIV infection phase less than 1 year
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hôpital Européen Marseille
Marseille, France, 13003
Actively Recruiting
Research Team
M
Myriam BENNANI
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here